Challenges in the design of multitarget drugs against multifactorial pathologies: A new life for medicinal chemistry?

Future Medicinal Chemistry

Volumn 5, Issue 1, 2013, Pages 5-7

  Costantino, Luca ^a   Barlocco, Daniela ^b  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

anticancer compounds; medicinal chemistry; multitarget drugs; network pharmacology

Indexed keywords

BACLOFEN; DEXANABINOL; NALTREXONE; PXT 3003; SORBITOL; SUNITINIB; UNCLASSIFIED DRUG;

CHEMISTRY; COMBINATORIAL CHEMISTRY; DRUG APPROVAL; DRUG EFFICACY; DRUG MARKETING; DRUG TARGETING; GLIOMA; HEREDITARY MOTOR SENSORY NEUROPATHY; HUMAN; MEDICAL RESEARCH; NONHUMAN; PATHOLOGY; PHARMACOPHORE; PHENOTYPE; PRIORITY JOURNAL; REVIEW; RISK FACTOR;

CHEMISTRY, PHARMACEUTICAL; DRUG DESIGN; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84871602057     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.12.193     Document Type: Review

References (20)

1. Scannell JW, Blankley A, Boldon H et al. Diagnosing the decline in pharmaceutical R&D efficiency. Nat. Rev. Drug Discov. 11(3), 191-200 (2012).
2. Swinney DC, Anthony J. How were new medicines discovered? Nat. Rev. Drug Discov. 10(7), 507-519 (2011).
3. Hase T, Tanaka H, Suzuki Y et al. Structure of protein interaction networks and their implications on drug design. PLoS Comput. Biol. 5, e1000550 (2009).
4. Kamb A, Wee S, Lengauer C. Why is cancer drug discovery so difficult? Nat. Rev. Drug Discov. 6(2), 115-120 (2007).
5. Marusyk A, Almendro V, Polyak K. Intra-tumor heterogeneity: A looking glass for cancer? Nat. Rev. Cancer 12(5), 323-334 (2012).
6. Barbachyn MR. Recent advances in the discovery of hybrid antibacterial agents. Ann. Rep. Med. Chem. 43, 281-290 (2008).
7. Costantino L, Barlocco D. Designed multiple ligands: Basic research vs clinical outcomes. Curr. Med. Chem. 19(20), 3353-3387 (2012).
8. Weis SM, Cheresh DA. Tumor angiogenesis: Molecular pathways and therapeutic targets. Nat. Med. 17(11), 1359-1370 (2011).
9. Sun CL, Christensen JG, McMahon G. Discovery and development of sunitinib (SUI11248): A multitarget tyrosine kinase inhibitor of tumor growth, survival, and angiogenesis. In: Kinase Inhibitor Drugs. Li R, Stafford JA (Eds). Wiley, NJ, USA, 3-40 (2009).
10. Swarbrick ME. The learning and evolution of medicinal chemistry against kinase targets. In: Kinase Drug Discovery. Ward RA, Goldberg F (Eds). Royal Society of Chemistry, Cambridge, UK, 79-95 (2012).
11. Paez-Ribes M, Allen E, Hudock J et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 15(3), 220-231 (2009).
12. Ebos JML, Lee CR, Cruz-Monoz W et al. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 15(3), 232-239 (2009).
13. Casanovas O. Limitations of therapies exposed. Nature 484(4) 44-46 (2012).
14. Chung AS, Kowanetz M, Wu X et al. Differential drug class-specific metastatic effects following treatment with a panel of angiogenesis inhibitors. J. Pathol. 227(4), 404-416 (2012).
15. Erlanson DA. Fragment-based drug discovery of kinase inhibitors. In: Kinase Inhibitor Drugs. Li R, Stafford JA (Eds). Wiley, NJ, USA, 461-484 (2009).
16. Lin X, Huang XP, Chen G et al. Life beyond kinases: Structure-based discovery of sorafenib as nanomolar antagonist of 5-HT receptors. J. Med. Chem. 55(12), 5749-5759 (2012).
17. Bottegoni G, Favia AD, Recanatini M et al. The role of fragment-based and computational methods in polypharmacology. Drug Discov. Today 17(1-2), 23-34 (2011).
18. Lee JA, Uhlik MT, Moxham CM et al. Modern phenotypic drug discovery is a viable, neoclassic pharma strategy. J. Med. Chem. 55(10), 4527-4538 (2012).
19. Klipp E, Wade RC, Kummer U. Biochemical network-based drug-target prediction. Curr. Opin. Biotechnol. 21(4), 511-516 (2010).
20. Network pharmacology moves into the clinic. Nat. Rev. Drug Disc. 11(8), 589 (2012).